<DOC>
	<DOCNO>NCT02650479</DOCNO>
	<brief_summary>Two-Part , Randomized , Placebo Active-Controlled , Double-Blind , Thorough QT Study Evaluating Effects Intravenous Exenatide Cardiac Repolarization Healthy Male Female Volunteers</brief_summary>
	<brief_title>Study Effects Intravenous Exenatide Cardiac Repolarization</brief_title>
	<detailed_description>This single-center Phase I study consist 2 part , Pilot Part Core Part . The Pilot Part study open-label , non-randomized , single-treatment design 10 healthy male female subject determine infusion regimen 6-h continuous IV infusion exenatide lead mean plasma steady state concentration 500 pg/mL . The Core part study double-blind ( except use open label active control moxifloxacin ) , randomize , placebo-controlled,3 period , 6-sequence , cross-over design 72 healthy male female subject evaluate whether exenatide therapeutic supra-therapeutic concentration pharmacological effect cardiac repolarization ( threshold value &gt; 10 msec ) .</detailed_description>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Body mass index ( BMI ) 19 35 kg/m2 inclusive . Women child bear potential use additional adequate method contraception study 1 additional menstrual cycle follow endofstudy ( EOS ) visit . Adequate method contraception woman child bear potential ( WOCBP ) include : mechanical product ( ie , intrauterine device [ IUD ] —copper IUD ) ; barrier method ( eg , diaphragm , condom , cervical cap ) spermacide . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( AP ) , bilirubin within normal range Screening . Fasting triglyceride within normal range Screening History type 1 type 2 diabetes , history hypoglycemia . History evidence myocardial infarction , congestive heart failure , syncope related heart arrhythmia , coronary revascularization ( coronary artery bypass graft percutaneous coronary intervention ) , unstable angina , cerebrovascular accident stroke TIA . History atrial fibrillation , flutter , nonsustained sustain VT . Personal family history sudden death long QT syndrome . History uncontrolled hypertension . History evidence acute chronic pancreatitis . History liver disease . Abnormal renal function . History medullary thyroid cancer personal family history multiple endocrine neoplasia type 2 . Thyroidstimulating hormone ( TSH ) outside normal limit Screening . Weight loss surgery . History malignancy ( include basal squamous cell carcinoma skin past 5 year ) . ( Subjects disease free great 5 year may include . ) History active alcohol within 1 year prior Screening . History drug abuse within 5 year prior Screening positive prestudy drug screen . Weekly consumption 14 alcoholic beverage females 21 alcoholic beverage male . Smoke 10 cigarette per day . Excessive xanthine consumption ( 5 cup coffee equivalent per day ) . History hypersensitivity medication use study . Women pregnant , lactating , plan become pregnant . History positive result screen test hepatitis B and/or hepatitis C and/or human immunodeficiency virus ( HIV ) . History evidence immunocompromised status . Prior current treatment GLP1 receptor agonist ( eg , Bydureon™ , Byetta® , Victoza® , Tanzeum® exogenous native GLP1 ) prior participation ITCA 650 clinical trial . Any gastrointestinal complaint within 7 day prior first dosing . Use medication within 14 day first dose hormone replacement therapy oral contraceptive . Chronic ( 8 consecutive day great ) treatment systemic corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>